Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer

Cancer

Volumn 107, Issue 4, 2006, Pages 746-756

  Ai, Zhihong ^a   Yin, Lianhua ^a   Zhou, Xianrong ^a   Zhu, Ying ^a   Zhu, Dongmei ^a   Yu, Yinhua ^b   Feng, Youji ^a  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Apoptosis; Endometrial cancer; Proliferation; RNA interference; Survivin

Indexed keywords

CASPASE 3; CASPASE 8; CYCLIN D1; EPIDERMAL GROWTH FACTOR; INHIBITOR OF APOPTOSIS PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; RETINOBLASTOMA PROTEIN; SURVIVIN; TRANSFORMING GROWTH FACTOR ALPHA;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIUM CANCER; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; RECOMBINANT PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADENOCARCINOMA; ADULT; AGED; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL PROLIFERATION; CYSTEINE PROTEINASE INHIBITORS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 33747161036     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22044     Document Type: Article

References (23)

1. Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1996. CA Cancer J Clin. 1996;46:5-28.
2. Lurain JR. Uterine cancer. In: Berek JS, editor. Novak's Gynecology. Baltimore: Williams & Wilkins, 1996:1057-1110.
3. Lax SF, Kendall B, Tashiro H, et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer. 2000;88:814-824.
4. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396:580-584.
5. Ling X, Bernacki RJ, Brattain MG, et al. Induction of survivin expression by Taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. J Biol Chem. 2004;279:15196-15203.
6. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3:46-54.
7. Altieri DC, Marchisio C. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest. 1999;79:1327-1333.
8. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003;22:8581-8589.
9. Tanaka K, Iwamoto S, Gon G, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000;6:127-134.
10. Pecorelli S, Benedet JL, Creasman WT, Shepherd JH. FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet. 1999;64:5-10.
11. Csaba M, Thomas K, Andreas K, et al. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer. 2002;100:30-36.
12. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917-921.
13. Kobayashi K, Hatkno M, Otaki M, et al. Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. Proc Natl Acad Sci U S A. 1999;96:1457-1462,
14. McManus M, Sharp P. Gene silencing in mammals by small interfering RNAs. Genetics. 2002;3:737-747.
15. Uren AG, Wong L, Pakusch M, et al. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol. 2000;10:1319-1328.
16. Grossman D, Kim PJ, Schechner JS, et al. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci U S A. 2001;98:635-640.
17. Olie RA, Simoes-Wust AR Baumann B, et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 2000;60:2805-2809.
18. Carvalho A, Carmena M, Sambade C, et al. Survivin is required for stable checkpoint activation in Taxol-treated HeLa cells. J Cell Sci. 2003;116:2987-2998.
19. Li F, Altieri DC. The cancer anti-apoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res. 1999;59:3143-3151.
20. Suzuki A, Hayashida M, Ito T, et al. Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation. Oncogene. 2000;19:3225-3234.
21. Pidgeon GP, Kandouz M, Meram A, Honn KV. Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. Cancer Res. 2002;62:2721-2727.
22. Shin S, Sung BJ, Cho YS, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry. 2001;40:1117-1123.
23. Lelle RJ, Talavera F, Gretz H, et al. Epidermal growth factor receptor expression in three different human endometrial cancer cell lines. Cancer. 1993;72:519-525.